HRG overexpression 293T lysate (whole cell) (ab94198)
Overview
-
Product name
HRG overexpression 293T lysate (whole cell) -
General notes
ab94198 is a 293T cell transfected lysate in which Human HRG has been transiently over-expressed using a pCMV-HRG plasmid. The lysate is provided in 1X Sample Buffer. Note: For more details about how the transfected lysate was prepared view preparation notes
-
Tested applications
Suitable for: WBmore details
Properties
-
Mycoplasma free
Yes -
Form
Liquid -
Storage instructions
Shipped on dry ice. Upon delivery aliquot and store at -20ºC. Avoid freeze / thaw cycles. -
Storage buffer
Constituents: 0.01% Bromophenol blue, 2.3% Beta mercaptoethanol, 2% Sodium lauryl sulfate, 0.788% Tris HCl, 10% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
Research areas
-
Background
Function: Plasma glycoprotein that binds a number of ligands such as heme, heparin, heparan sulfate, thrombospondin, plasminogen, and divalent metal ions. Binds heparin and heparin/glycosaminoglycans in a zinc-dependent manner. Binds heparan sulfate on the surface of liver, lung, kidney and heart endothelial cells. Binds to N-sulfated polysaccharide chains on the surface of liver endothelial cells. Inhibits rosette formation. Acts as an adapter protein and is implicated in regulating many processes such as immune complex and pathogen clearance, cell chemotaxis, cell adhesion, angiogenesis, coagulation and fibrinolysis. Mediates clearance of necrotic cells through enhancing the phagocytosis of necrotic cells in a heparan sulfate-dependent pathway. This process can be regulated by the presence of certain HRG ligands such as heparin and zinc ions. Binds to IgG subclasses of immunoglobins containing kappa and lambda light chains with different affinities regulating their clearance and inhibiting the formation of insoluble immune complexes. Tethers plasminogen to the cell surface. Binds T-cells and alters the cell morphology. Modulates angiogenesis by blocking the CD6-mediated antiangiongenic effect of thrombospondins, THBS1 and THBS2. Acts as a regulator of the vascular endothelial growth factor (VEGF) signaling pathway; inhibits endothelial cell motility by reducing VEGF-induced complex formation between PXN/paxillin and ILK/integrin-linked protein kinase and by promoting inhibition of VEGF-induced tyrosine phosphorylation of focal adhesion kinases and alpha-actinins in endothelial cells. Also plays a role in the regulation of tumor angiogenesis and tumor immune surveillance. Normalizes tumor vessels and promotes antitumor immunity by polarizing tumor-associated macrophages, leading to decreased tumor growth and metastasis. Tissue specificity: Expressed in macrophages and in malignant cells. Expressed by the liver and secreted in plasma (at protein level). Disease: Thrombophilia due to histidine-rich glycoprotein deficiency Similarity: Contains 2 cystatin domains. Domain: The His/Pro-rich (HRR) region contains approximately 12 tandem internal repeats of the 5-residue G[H/P][H/P]PH consensus sequence. HRR binds heparan sulfate and possesses antiangiogenic, antibacterial and antifungal properties through binding Candida cells, and preferentially lysing the ergosterol-containing liposomes at low pH. The tandem repeats also bind divalent metal ions and heme. The cystatin domains can also bind heparan sulfate. Binding is enhanced in the presence of zinc ions. PTM: Proteolytic cleavage produces several HRG fragments which are mostly disulfide-linked and, therefore, not released. Cleavage by plasmin is inhibited in the presence of heparin, zinc ions or in an acidic environment. Cleavage reduces binding of HRG to heparan sulfate, but enhances the ability of HRG to bind and tether plasminogen to the cell surface. On platelet activation, releases a 33 kDa antiangiogenic peptide which encompasses the HRR. Also cleaved in the C-terminal by plasmin. N-glycosylated.
Associated products
-
Corresponding Antibody
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab94198 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
Use at an assay dependent dilution.
|
Notes |
---|
WB
Use at an assay dependent dilution. |
Images
-
ab94198 at 15µg/lane on an SDS-PAGE gel.
-
All lanes : Anti-HRG antibody (ab67807) at 1/500 dilution
Lane 1 :HRG overexpression 293T lysate (whole cell) (ab94198)
Lane 2 : 293T non-transfected lysate
Lysates/proteins at 25 µg per lane.
Secondary
All lanes : Goat Anti-mouse IgG (H and L) HRP conjugated at 1/2500 dilution
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab94198 has not yet been referenced specifically in any publications.